Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Lopez, Joseph; Cortes, Henry; García-Ceballos, E.; Quintero-Pizarro, L.

doi:10.20986/resed.2017.3625/2017

Cited by 4 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a case series of 45 patients with neuropathic pain of different aetiologies, such as post‐herpetic neuralgia, chronic post‐surgical pain or traumatic peripheral nerve injury, showed a significant pain relief at 3 months after an injection of PRP in the territory of injured nerve. In this study, this benefit was observed for the majority (>80%) of patients (Correa López et al., 2017).…”

Section: Platelet‐rich Plasma and Neuropathic Painsupporting

confidence: 58%

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Bohren

Timbolschi

Müller

et al. 2021

European Journal of Pain

View full text Add to dashboard Cite

Background and Objective Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. A number of preclinical studies have provided evidence for the involvement of cytokines, predominantly secreted by a variety of immune cells and by glial cells from the nervous system, in neuropathic pain conditions. Clinical trials and the use of anti‐cytokine drugs in different neuropathic aetiologies support the relevance of cytokines as treatment targets. However, the use of such drugs, in particularly biotherapies, can provoke notable adverse effects. Moreover, it is challenging to select one given cytokine as a target, among the various neuropathic pain conditions. It could thus be of interest to target other proteins, such as growth factors, in order to act more widely on the neuroinflammation network. Thus, platelet‐rich plasma (PRP), an autologous blood concentrate, is known to contain a natural concentration of growth factors and immune system messengers and is widely used in the clinical setting for tissue regeneration and repair. Database and Data Treatment In the present review, we critically assess the current knowledge on cytokines in neuropathic pain by taking into consideration both human studies and animal models. Results This analysis of the literature highlights the pathophysiological importance of cytokines. We particularly highlight the concept of time‐ and tissue‐dependent cytokine activation during neuropathic pain conditions. Conclusion Thus, direct or indirect cytokines modulation with biotherapies or growth factors appears relevant. In addition, we discuss the therapeutic potential of localized injection of PRP as neuropathic pain treatment by pointing out the possible link between cytokines and the action of PRP. Significance Preclinical and clinical studies highlight the idea of a cytokine imbalance in the development and maintenance of neuropathic pain. Clinical trials with anticytokine drugs are encouraging but are limited by a 'cytokine candidate approach' and adverse effect of biotherapies. PRP, containing various growth factors, is a new therapeutic used in regenerative medicine. Growth factors can be also considered as modulators of cytokine balance. Here, we emphasize a potential therapeutic effect of PRP on cytokine imbalance in neuropathic pain. We also underline the clinical interest of the use of PRP, not only for its therapeutic effect but also for its safety of use.

show abstract

Section: Platelet‐rich Plasma and Neuropathic Painsupporting

confidence: 58%

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Bohren

Timbolschi

Müller

et al. 2021

European Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Our reason for changing the intradiscal injection technique, preferring the epidural space was that, compared to intradiscal injection, growth factors by epidural route would fulfill an effective outcome by acting not only on the discs, but also over the facet joints and the ligamentum flavum, and, because of its anti-inflammatory activity. That further study had allowed us to confirm that this technique -epidural PRP-help with relieving the neuropathic pain (NP) associated to IDD [29].…”

Section: Why Pdgf Into the Epidural Space?mentioning

confidence: 87%

“…TGF-β1 acted as a powerful neuromodulator and rapidly (within minutes) suppressed chronic constriction injury-evoked spinal synaptic plasticity and dorsal root ganglion neuronal hyperexcitability, alleviating early-and late-phase neuropathic pain symptoms, such as allodynia and hyperalgesia, for several weeks in murine models. These previous studies -in murine models-, allowed us to raise the hypothesis that PRP could help us to relieve neuropathic pain that is associated with DDD [29].…”

Section: The Anti-inflammatory Effect With Prgfmentioning

confidence: 99%

“…However, early in vivo studies used intradiscal injection of PRGF. These early documents concluded that intradiscal injection of autologous PRGF in patients with low back pain is safe and free of adverse events [29][30][31][32][33]. However, the intradiscal injection of PRGF technique is a more laborious proceeding and probably limits the effects.…”

Section: Epidural Prpmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives of Cell-Based Therapy for Degenerative Diseases of the Spine: The Reason for Choosing the Epidural Space

Correa¹,

Cortes²,

Correa³

et al. 2023

Epidural Administration - New Perspectives and Uses

Self Cite

View full text Add to dashboard Cite

Intervertebral disc degeneration (IDD) is a chronic disease that causes significant disability and dependence and exerts a high cost on society. Concerning IDD, it is the most common cause of back pain, involving any segment of the spine. It is one of the most frequent reasons for consultation in the general population, second only to headache, affecting 80–85% of people throughout life. Current therapeutic strategies focused on IDD are primarily conservative, including physical therapy and antiinflammatory medication. Surgical techniques intend to stabilize the spine and/or decompress the spinal or foraminal canal, searching for relieve of symptoms, and, however, do not address the cause of the degeneration and even accelerate the degeneration of adjacent segments. Understanding of the biology of platelet-rich plasma (PRP) and other growth factors directed us to use of PRP as a promising biological therapeutic strategy for enhancing the regenerative process, searching for the healing of the intervertebral disc. With current few in vitro studies, and fewer clinical studies linking the bases of regenerative medicine (RM) in the management of degenerative disc disease, our pioneering research was to state the bases, fundamentals, results, and the new trends around the RM techniques focused on the pathology of the spinal canal, taking the advantages that offer the epidural route.

show abstract

“…Peripheral neuropathy is a common complication of diabetes mellitus, with a wide spectrum of clinical manifestations that encompass focal and multifocal forms resulting in an impaired quality of life, as well as in increased morbidity and mortality with no available disease-modifying treatments ( 1 ). Platelet-rich plasma (PRP) has been used in the treatment of diabetic neuropathy ( 2 ) and neuropathic pain ( 3 ). Plasma rich in growth factors (PRGF) is a subtype of PRP that stimulates tissue regeneration and may promote neuronal healing and survival.…”

Section: Introductionmentioning

confidence: 99%

Use of plasma rich in growth factors for symptoms of diabetic neuropathy

Roman¹,

Broyer

2023

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

Summary Painful peripheral polyneuropathy is a common complication of diabetes mellitus (DM) and is a significant source of chronic disability and remains a challenging condition with no available disease-modifying treatment. In the present case report, we describe the treatment of a patient featuring painful diabetic neuropathy with perineural injections of autologous plasma rich in growth factors (PRGF). At one-year post-procedure, the patient exhibited improved scores on the neuropathic pain scale and improvement in the activity level. Learning points Plasma rich in growth factors (PRGF) is an autologous product that can be prepared and administered in a physician’s office. PRGF can be infiltrated as a liquid, creating a three-dimensional gel scaffold in the body. PRGF releases growth factors involved in nerve healing. PRGF may be established as a potent alternative treatment of painful diabetic polyneuropathy.

show abstract

Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Cited by 4 publications

References 54 publications

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Platelet‐rich plasma and cytokines in neuropathic pain: A narrative review and a clinical perspective

Perspectives of Cell-Based Therapy for Degenerative Diseases of the Spine: The Reason for Choosing the Epidural Space

Use of plasma rich in growth factors for symptoms of diabetic neuropathy

Contact Info

Product

Resources

About